News

23 Sep 2013
Cellectis bioresearch launches Compact TALEN™ the next generation of TAL effector nucleases
Paris (France), September 23, 2013 - Cellectis bioresearch, a subsidiary of Cellectis Group (Alternext: ALCLS), the genome engineering specialist, announces the launch of a...
26 Jun 2013
Cellectis has successfully engineered the genome of photosynthetic algae with a view to biofuel production
Paris, June 26, 2013 - Cellectis (Alternext: ALCLS), the genome engineering specialist, announced today that it has successfully used engineered nucleases to genetically reprogram...
28 May 2013
TAL-effector nuclease: The USPTO issues a third patent licensed to Cellectis
Cellectis (NYSE PA: ALCLS), the global genome engineering specialist, announces the issuance by the USPTO on May 28, 2013 of a 3rd US patent (US 8,450,471) directed to TAL-...
21 May 2013
Compact TALEN™: the next generation of TAL effector nucleases
Cellectis (NYSE PA: ALCLS), the global genome engineering specialist, announced today that the high-impact scientific journal Nature Communications has published an in-house study...
16 May 2013
TAL-effector nuclease: Issuance by the USPTO of Two New Patents - Cellectis provides its customers TALEN™ product under license of these patents to easily achieve any genome engineering projects.
New Brighton, May 16, 2013 – Cellectis (NYSE PA: ALCLS), the global genome engineering specialist, announced the issuance by the USPTO on May 14th, 2013 of two new US...
17 Apr 2013
Cellectis bioresearch launches VizuCELL cell lines for live cell imaging
Paris (France), April, 17th 2013 - Cellectis bioresearch, a subsidiary of Cellectis Group (Alternext: ALCLS), the genome engineering specialist, announces the launch of VizuCELL...

Pages

Copyright 2012 Cellectis
Design & Development by EtonDigital